Delving into the Latest Updates on WJ-Pure with Synapse

Overview

Basic Info

Drug Type

Mesenchymal stem cell therapy

Synonyms

Target-

Action-

Mechanism-

Therapeutic Areas

Respiratory DiseasesImmune System DiseasesNervous System Diseases+ [3]

Active Indication

Pulmonary Disease, Chronic ObstructiveAlzheimer DiseaseMuscular Dystrophy, Duchenne+ [1]

Inactive Indication

COVID-19COVID-19 respiratory infectionPulmonary Fibrosis+ [1]

Originator Organization

Vitti Labs LLC.

Active Organization

Vitti Labs LLC.

Inactive Organization-

Drug Highest PhaseIND Application

First Approval Date-

Regulation-

Login to view timeline

Recent advances have been made in prevention of the viral infection via vaccines but there is still need for effective treatment options for patients. Novel therapies need to be developed to further improve clinical outcomes. The biggest medical challenge in the response to COVID-19 is ARDS requiring hospitalization in an intensive care setting and ventilator dependence. Intravenously administered umbilical cord derived exosomes and stem cells have been reported in literature to alleviate pulmonary distress in such patients.
The purpose of this study is to explore the safety and benefits of intravenous administration of WJPure and EVPure in the treatment of COVID-19 patients with moderate to severe ARDS. .

Start Date20 Mar 2025

Sponsor / Collaborator

Vitti Labs LLC.

NCT05387239

/ SuspendedPhase 2

Safety and Effectiveness of VL-PX10 + VL-P22 Treatment on Pulmonary Fibrosis Secondary to Covid-19

The COVID-induced fibrotic lung damage continues long after viral infection has subsided and is exhibited by severe respiratory pathology and concomitant symptoms. The long-lasting sequelae in patients who have recovered from severe COVID indicate that there is a 30% chance of developing a persistent respiratory system pathology and a 10% chance of developing a severe pathology. The symptoms of lung fibrosis include a severe disruption of respiration, reduction of exercise tolerance, and concomitant development of persistent fibrotic lung damage. This study intends to evaluate benefits of a combination of VL-P22 and VL-PX10 in Covid-19 patients exhibiting pulmonary fibrosis.

Start Date30 Nov 2022

Sponsor / Collaborator

Vitti Labs LLC.

100 Clinical Results associated with WJ-Pure

Login to view more data

100 Translational Medicine associated with WJ-Pure

Login to view more data

100 Patents (Medical) associated with WJ-Pure

Login to view more data

7

Literatures (Medical) associated with WJ-Pure

01 Dec 2022·BMC Oral Health

Efficiency of biofilm removal by combination of water jet and cold plasma: an in-vitro study

Article

Author: Eberhard, Christian ; Holtfreter, Birte ; Jablonowski, Lukasz ; Vilardell Scholten, Laura ; Seifert, Leo ; Gerling, Torsten ; Kocher, Thomas ; Pitchika, Vinay ; Schlüter, Rabea ; Matthes, Rutger

AbstractBackgroundPeri-implantitis therapy is a major problem in implantology. Because of challenging rough implant surface and implant geometry, microorganisms can hide and survive in implant microstructures and impede debridement. We developed a new water jet (WJ) device and a new cold atmospheric pressure plasma (CAP) device to overcome these problems and investigated aspects of efficacy in vitro and safety with the aim to create the prerequisites for a clinical pilot study with these medical devices.MethodsWe compared the efficiency of a single treatment with a WJ or curette and cotton swab (CC) without or with adjunctive use of CAP (WJ + CAP, CC + CAP) to remove biofilm in vitro from rough titanium discs. Treatment efficacy was evaluated by measuring turbidity up to 72 h for bacterial re-growth or spreading of osteoblast-like cells (MG-63) after 5 days with scanning electron microscopy. With respect to application safety, the WJ and CAP instruments were examined according to basic regulations for medical devices.ResultsAfter 96 h of incubation all WJ and CC treated disks were turbid but 67% of WJ + CAP and 46% CC + CAP treated specimens were still clear. The increase in turbidity after WJ treatment was delayed by about 20 h compared to CC treatment. In combination with CAP the cell coverage significantly increased to 82% (WJ + CAP) or 72% (CC + CAP), compared to single treatment 11% (WJ) or 10% (CC).ConclusionThe newly developed water jet device effectively removes biofilm from rough titanium surfaces in vitro and, in combination with the new CAP device, biologically acceptable surfaces allow osteoblasts to grow. WJ in combination with CAP leads to cleaner surfaces than the usage of curette and cotton swabs with or without subsequent plasma treatment. Our next step will be a clinical pilot study with these new devices to assess the clinical healing process.

01 Jan 2022·International journal of molecular and cellular medicine

Improvement of Corneal Nerve Regeneration in Diabetic Rats Using Wharton's Jelly-Derived Mesenchymal Stem Cells and their Conditioned Medium.

Article

Author: Naroeni, Aroem ; Dewayani Antarianto, Radiana ; Ariesta Shinta Dewi, Pitra ; Sitompul, Ratna ; Adiwinata Pawitan, Jeanne

To investigate the efficacy of Wharton's jelly mesenchymal stem cells (WJSCs) and their conditioned medium (CM) for corneal nerve regeneration in rats with diabetic keratopathy. Streptozotocin (STZ)-induced male diabetic (DM) rats (250-300 g) were divided into four groups (n=7/group): Control, DM, DM with WJSCs (DM+WJ), and DM with CM treatment (DM+CM). DM+WJ and DM+CM group received WJSCs or CM, respectively, topically with eye drops. Corneal sensibility, corneal epithelial layer integrity, histology, expression of GAP-43 and TUBB3 on mRNA level and their immunohistochemical expression were examined after two weeks of treatment. There were changes in corneal sensibility and corneal integrity between normal control and diabetic groups with/without WJSC or CM injection. Total central corneal thickness was significantly higher in DM+CM (249.81 ± 43.85 μm) than in control (174.72 ± 44.12 μm, P=0.004) and DM groups (190.15 ± 9.63 μm, P=0.03). GAP-43 mRNA expression levels of DM+WJ and DM+CM groups were higher compared with DM and control groups. TUBB3 mRNA level was increased after CM (P=0.047), but not after WJSCs treatment (P=1.00). GAP-43 and TUBB3 immunohistochemical expression of nerve fibers along the epithelial layer significantly increased in DM+WJ and DM+CM compared with DM group. Our findings showed that WJSCs and their CM improved corneal nerve regeneration in rats with diabetic keratopathy.

01 Sep 2021·Contemporary Clinical Trials Communications

Evaluation of immediate and short-term efficacy of DualStim therapy with and without intracavernosal umbilical cord-derived Wharton's jelly in patients with erectile dysfunction: Study protocol for a randomized controlled trial

Article

Author: Rodriguez, Hugo C ; Gaines, Richard ; Gupta, Ashim ; Delfino, Kristin ; Levy, Howard J ; El-Amin, Saadiq F

INTRODUCTIONErectile dysfunction (ED) affects a significant portion of the United States population and causes negative psychological burdens that affects men and their partner's quality of life and satisfaction. Extracorporeal shock therapy (ESWT) utilizing focused ESWT and radial ESWT in Low-intensity shock wave therapy has been used to treat ED with some success. Wharton's Jelly (WJ) is a biologic substance with large amounts of stem cells, growth factors, cytokines and extracellular components. The use of combined focused and radial ESWT (DualStim therapy) with injected WJ have potential uses in ED that may have advantages over current treatments.MATERIALSA randomized, single-blinded, controlled clinical trial will be conducted to evaluate the efficacy and safety of DualStim therapy and intracavernosal injection of WJ in moderate to severe ED. A total of 60 patients with moderate to severe ED will be enrolled and treated with DualStim therapy with intracavernosal injection of WJ or saline for a period of 7 weeks. The International Index of Erectile Function - Erectile Function score will be used to gauge the treatment related changes in relation to the subject's baseline. The scores will be recorded at baseline and compared to follow-ups 1,3 and 6 months post-treatment. Any adverse events or severe adverse events will be recorded in the corresponding case report forms. Sexual Encounter Profile, as well as the Global Assessment Questionnaire and the Erection Hardness Score will be used to determine the sexual activity improvement from baseline leading to optimal penetration at follow-ups 1,3 and 6 months post-treatment.DISCUSSIONThis clinical trial is one of the first studies to determine the immediate and short-term efficacy of DualStim therapy, with and without intracavernosal injection of formulated umbilical cord-derived WJ to improve and/or restore erectile function in patients with moderate to severe ED. This study will also provide insight into the safety and efficacy of WJ. We anticipate clinically significant improvement in patients suffering from moderate and severe ED treated with DualStim therapy with WJ compared to their baseline and DualStim with saline.

100 Deals associated with WJ-Pure

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Pulmonary Disease, Chronic Obstructive	IND Application	United States	Vitti Labs LLC.	30 Jan 2022
Alzheimer Disease	Preclinical	United States	Vitti Labs LLC.	30 Jan 2022
Muscular Dystrophy, Duchenne	Preclinical	United States	Vitti Labs LLC.	30 Jan 2022
Osteoarthritis	Preclinical	United States	Vitti Labs LLC.	30 Jan 2022
Respiratory Distress Syndrome, Acute	Discovery	United States	Vitti Labs LLC.	20 Mar 2025
COVID-19	Discovery	United States	Vitti Labs LLC.	30 Nov 2022
COVID-19 respiratory infection	Discovery	United States	Vitti Labs LLC.	30 Nov 2022
Pulmonary Fibrosis	Discovery	United States	Vitti Labs LLC.	30 Nov 2022